சிகிச்சை ஆஃப் ஒற்றைத் தலைவலி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சிகிச்சை ஆஃப் ஒற்றைத் தலைவலி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சிகிச்சை ஆஃப் ஒற்றைத் தலைவலி Today - Breaking & Trending Today

Cipla receives USFDA approval for Sumatriptan Nasal Spray

Cipla has received final approval for its
Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the
United States Food and Drug Administration (USFDA).
Cipla s Sumatriptan Nasal Spray USP, 20 mg is an AB-rated generic therapeutic
equivalent version of GlaxoSmithKline s Imitrex Nasal Spray.
Imitrex Nasal Spray is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for
acute treatment of migraine with or without aura in adults.
According to IQVIA (IMS Health), Imitrex Nasal Spray 20mg and its generic equivalents
had US sales of approximately $53.3M for the 12-month period ending December 2020.
Powered by Capital Market - Live News ....

United States , Drug Administration , Abbreviated New Drug Application , Sumatriptan Nasal Spray , United States Food , Imitrex Nasal , Nasal Spray , Imitrex Nasal Spray , Capital Market , Health Care , Nifty 50 , Pharmaceutical Industry , Food And Drug Administration , New Drug Application , Pharmaceuticals Nec , Treatment Of Migraine , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது மாநிலங்களில் உணவு , நாசி தெளிப்பு , மூலதனம் சந்தை , ஆரோக்கியம் பராமரிப்பு , மருந்து தொழில் , புதியது மருந்து விண்ணப்பம் , மருந்துகள் கழுத்து , சிகிச்சை ஆஃப் ஒற்றைத் தலைவலி ,

FDA approves Indian company's triple-combination pills for migraine

Many patients are experiencing worsening migraine symptoms during covid-19 pandemic .
Is the coronavirus pandemic and the new normal giving you a headache? You’re not alone. Headache specialists worldwide have reported witnessing an increase in migraines or worsening symptoms during the pandemic. Several factors related to the pandemic, such as increased stress levels, more screen time, changes in routine, are blamed for the rise in the number. Stress is thought to be one of the most common triggers of migraine headache and the COVID-19 pandemic, many people are facing with financial and emotional stress. Once it hits, migraine headaches can last for hours or even days. Unfortunately, there is no cure for migraine. But a number of OTC or prescription medications are available to help ease the migraine symptoms, including severe throbbing headache, nausea, vomiting, and nasal congestion. Now, an Indian company has come up with a new triple-combination drug for the treatment ....

About The , Pills For Migraine , Triple Combination Drug For Migraine , Ease The Migraine Symptoms , Treatment Of Migraine , மாத்திரைகள் க்கு ஒற்றைத் தலைவலி , மூன்று சேர்க்கை மருந்து க்கு ஒற்றைத் தலைவலி , எளிதாக தி ஒற்றைத் தலைவலி அறிகுறிகள் , சிகிச்சை ஆஃப் ஒற்றைத் தலைவலி ,

Granules India receives USFDA approval for Acetaminophen, Aspirin and Caffeine Tablets

Granules India announced today that the US Food & Drug Administration (US FDA) has approved its
Abbreviated New Drug Application (ANDA) for Acetaminophen, Aspirin and Caffeine Tablets USP, 250
mg/250 mg/65 mg (OTC).
It is bioequivalent to the reference listed drug product (RLD), Excedrin Migraine
Tablets, 250 mg/250 mg/65 mg, of GlaxoSmithKline Consumer Healthcare. The product would be
manufactured at the company s Hyderabad facility and is expected to be launched shortly.
Acetaminophen, Aspirin and Caffeine Tablets are indicated for the treatment of migraine.
Granules now has a total of 38 ANDA approvals from US FDA (37 Final approvals and 1 tentative
approval)
Powered by Capital Market - Live News ....

Andhra Pradesh , Us Food Drug Administration , Granules India , Drug Administration , Abbreviated New Drug Application , Caffeine Tablets , Excedrin Migraine Tablets , Glaxosmithkline Consumer , Capital Market , Combination Drugs , Magnesium In Biology , Treatment Of Migraine , Drug Product , Hyderabad Facility , ஆந்திரா பிரதேஷ் , துகள்கள் இந்தியா , காஃபின் மாத்திரைகள் , கிளாக்சோஸ்மித்க்லைன் நுகர்வோர் , மூலதனம் சந்தை , சேர்க்கை மருந்துகள் , வெளிமம் இல் உயிரியல் , சிகிச்சை ஆஃப் ஒற்றைத் தலைவலி , மருந்து ப்ராடக்ட் , ஹைதராபாத் வசதி , ஒற்றைத் தலைவலி ,